Adjuvant therapy for melanoma: how should we respond to high-dose interferon?
1998

Adjuvant Therapy for Melanoma: High-Dose Interferon

Sample size: 287 publication Evidence: high

Author Information

Author(s): PG de Takats, MV Williams, R Hawkins

Primary Institution: Oncology Centre, Addenbrooke's NHS Trust

Hypothesis

Does high-dose interferon alpha 2b improve survival in patients at high risk of recurrence after surgery for melanoma?

Conclusion

High-dose interferon alpha 2b therapy shows a significant survival benefit in patients with high-risk melanoma.

Supporting Evidence

  • High-dose interferon alpha 2b therapy showed significant prolongation of relapse-free and overall survival.
  • The study is the first to demonstrate a durable statistically significant survival benefit from any medical therapy after surgery for melanoma.
  • Over 50% of patients with thick primary tumors or regional lymph node involvement relapse or die within 2 years of surgery.

Takeaway

This study found that giving high-dose interferon can help people with melanoma live longer after surgery.

Methodology

Randomized controlled trial comparing high-dose interferon alpha 2b to observation in melanoma patients after surgery.

Potential Biases

Potential bias due to the one-tailed test assumption that treatment would be superior.

Limitations

The study's findings may not be generalizable due to the specific patient population and treatment protocols used.

Participant Demographics

Patients with thick primary or regional lymph node-positive malignant melanoma, median age below 50.

Statistical Information

P-Value

0.0023 for relapse-free survival, 0.0237 for overall survival

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication